CIBC Private Wealth Group LLC increased its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 2.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,628 shares of the financial services provider’s stock after purchasing an additional 375 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in iShares Biotechnology ETF were worth $1,837,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of IBB. HHM Wealth Advisors LLC lifted its position in shares of iShares Biotechnology ETF by 200.0% during the 4th quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock worth $30,000 after purchasing an additional 150 shares during the last quarter. VSM Wealth Advisory LLC purchased a new position in iShares Biotechnology ETF in the fourth quarter valued at $30,000. Bradley & Co. Private Wealth Management LLC acquired a new stake in iShares Biotechnology ETF in the fourth quarter valued at $32,000. Newbridge Financial Services Group Inc. purchased a new stake in iShares Biotechnology ETF during the 4th quarter worth about $33,000. Finally, Hager Investment Management Services LLC acquired a new position in shares of iShares Biotechnology ETF during the 4th quarter worth about $34,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Trading Down 2.4 %
IBB stock opened at $123.79 on Friday. The stock has a market cap of $5.85 billion, a P/E ratio of 27.83 and a beta of 0.84. iShares Biotechnology ETF has a twelve month low of $123.21 and a twelve month high of $150.57. The company’s 50 day moving average is $135.35 and its two-hundred day moving average is $138.39.
iShares Biotechnology ETF Increases Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- The 3 Best Fintech Stocks to Buy Now
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- 3 Healthcare Dividend Stocks to Buy
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.